(Reuters) – Drug developer 89Bio Inc said on Wednesday its treatment for a liver disease called non-alcoholic steatohepatitis met the main goals of a mid-stage trial, sending its shares up 50% in premarket trading.
The company’s experimental drug, Pegozafermin, demonstrated at least one-stage fibrosis improvement without worsening of NASH and NASH resolution without worsening of fibrosis in both trial doses.
89Bio said the data supports advancement to late-stage development.
(Reporting by Pratik Jain in Bengaluru; Editing by Sriraj Kalluvila)
